$GLYC
GLYCOMIMETICS INC

2015 Q1 Form 10-K Financial Statement

#000119312515093802 Filed on March 16, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 Q4 2014 Q3
Revenue $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.900M $2.120M $1.648M
YoY Change 55.11% 158.54% 106.0%
% of Gross Profit
Research & Development $5.208M $5.280M $5.051M
YoY Change 34.16% 69.23% 71.02%
% of Gross Profit
Depreciation & Amortization $44.25K $50.00K $40.79K
YoY Change 27.8% 66.67% 22.47%
% of Gross Profit
Operating Expenses $5.208M $7.400M $6.699M
YoY Change 1.98% 87.82% 78.48%
Operating Profit -$7.113M -$6.699M
YoY Change 39.28% 81.01%
Interest Expense $0.00 $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $3.564K $4.827K
YoY Change -25.33% 30068.75%
Pretax Income -$7.110M -$7.390M -$6.694M
YoY Change 39.41% 90.96% 80.88%
Income Tax $0.00 -$76.76K
% Of Pretax Income
Net Earnings -$7.109M -$7.394M -$6.618M
YoY Change 39.34% 91.19% 78.81%
Net Earnings / Revenue
Basic Earnings Per Share -$0.39 -$0.35
Diluted Earnings Per Share -$375.0K -$0.39 -$0.35
COMMON SHARES
Basic Shares Outstanding 18.99M shares 18.89M shares 18.89M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q1 2014 Q4 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $46.60M $55.20M $61.40M
YoY Change -18.25% 2300.0%
Cash & Equivalents $46.57M $55.20M $61.36M
Short-Term Investments $0.00
Other Short-Term Assets $800.0K $900.0K $600.0K
YoY Change 14.29% -65.38%
Inventory
Prepaid Expenses $704.4K $819.9K $507.7K
Receivables
Other Receivables $1.000K $22.33K $22.39K
Total Short-Term Assets $47.34M $56.12M $61.95M
YoY Change -17.93% 1049.04%
LONG-TERM ASSETS
Property, Plant & Equipment $420.4K $452.3K $481.9K
YoY Change 10.89% 13.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $700.0K $700.0K
YoY Change
Total Long-Term Assets $1.117M $1.149M $481.9K
YoY Change 194.62% 187.34%
TOTAL ASSETS
Total Short-Term Assets $47.34M $56.12M $61.95M
Total Long-Term Assets $1.117M $1.149M $481.9K
Total Assets $48.46M $57.26M $62.43M
YoY Change -16.54% 983.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.183M $874.0K $583.7K
YoY Change -34.14% -23.66%
Accrued Expenses $2.626M $4.736M $3.446M
YoY Change 369.0% 590.59%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.104M $6.461M $4.714M
YoY Change 55.31% 183.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.104M $6.461M $4.714M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $4.104M $6.461M $4.723M
YoY Change 51.43% 171.9%
SHAREHOLDERS EQUITY
Retained Earnings -$81.51M -$74.40M -$67.00M
YoY Change 17.58%
Common Stock $19.01K $125.2M $18.90K
YoY Change 1.2% 8767435.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $44.36M $50.80M $57.71M
YoY Change
Total Liabilities & Shareholders Equity $48.46M $57.26M $62.43M
YoY Change -16.54% 983.83%

Cashflow Statement

Concept 2015 Q1 2014 Q4 2014 Q3
OPERATING ACTIVITIES
Net Income -$7.109M -$7.394M -$6.618M
YoY Change 39.34% 91.19% 78.81%
Depreciation, Depletion And Amortization $44.25K $50.00K $40.79K
YoY Change 27.8% 66.67% 22.47%
Cash From Operating Activities -$8.710M -$6.150M -$4.760M
YoY Change 236.68% 10.41% 40.41%
INVESTING ACTIVITIES
Capital Expenditures $2.339K -$10.00K -$100.0K
YoY Change -83.2% 0.0% 150.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 -$10.00K -$100.0K
YoY Change -100.0% 0.0% 150.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 80.00K 0.000 0.000
YoY Change -99.86% -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -8.710M -6.150M -4.760M
Cash From Investing Activities 0.000 -10.00K -100.0K
Cash From Financing Activities 80.00K 0.000 0.000
Net Change In Cash -8.630M -6.160M -4.860M
YoY Change -115.79% 14.5% 57.28%
FREE CASH FLOW
Cash From Operating Activities -$8.710M -$6.150M -$4.760M
Capital Expenditures $2.339K -$10.00K -$100.0K
Free Cash Flow -$8.712M -$6.140M -$4.660M
YoY Change 234.97% 10.43% 39.1%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
8456917
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28172174
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
12528384
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17372832
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18994838 shares
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
607500
CY2006Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
25.92
CY2014Q2 dei Entity Public Float
EntityPublicFloat
79100000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1426593 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1426593 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70258276 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
26453123
CY2013Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
104191
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
755911
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2279299
CY2013Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
344467
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
1428
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1144895
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-63275409
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
685746
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
2907419
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
356345
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5283474
CY2013Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
68821
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
66150674
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
54211
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2013Q4 us-gaap Liabilities
Liabilities
2376055
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
96756
CY2013Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
155935
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2310603
CY2013Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
2200000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
399799
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
68821
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
26521944
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2573072
CY2013Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1000
CY2013Q4 us-gaap Disposal Group Including Discontinued Operation Long Lived Assets
DisposalGroupIncludingDiscontinuedOperationLongLivedAssets
0
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1155710
CY2013Q4 us-gaap Deferred Rent Receivables Net
DeferredRentReceivablesNet
200947
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
18041784
CY2013Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
4552161
CY2013Q4 us-gaap Assets
Assets
5283474
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2013Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
94754
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
24151
CY2013Q4 us-gaap Assets Current
AssetsCurrent
4883675
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
171814
CY2013Q4 glyc Restricted Deposits
RestrictedDeposits
82700
CY2013Q4 glyc Prepaid Initial Public Offering Costs
PrepaidInitialPublicOfferingCosts
2222804
CY2013Q4 glyc Shares Authorized
SharesAuthorized
130601021 shares
CY2013Q4 glyc Deferred Tax Assets Capitalized Start Up Costs
DeferredTaxAssetsCapitalizedStartUpCosts
3541858
CY2013Q4 glyc Deferred Tax Assets Patent Amortization
DeferredTaxAssetsPatentAmortization
282727
CY2013Q4 glyc Deferred Tax Assets Deferred Rent
DeferredTaxAssetsDeferredRent
79263
CY2013Q4 glyc Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
68821
CY2013Q4 glyc Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
114005
CY2013Q4 glyc Accrued Franchise And Other Taxes
AccruedFranchiseAndOtherTaxes
5250
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18939838 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18939838 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
32655210
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
97012
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
905479
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
2672776
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6460545
CY2014Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
753786
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
18940
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
874028
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-74396975
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
640914
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4735719
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
50803428
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
151415
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
5725259
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
656937
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
625282
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
57263973
CY2014Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
10816
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
125181463
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
77273
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
610031
CY2014Q4 us-gaap Liabilities
Liabilities
6460545
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
519319
CY2014Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
168009
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55198923
CY2014Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
55000000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
452270
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
32666026
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
916249
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
52717
CY2014Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
16293
CY2014Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
696531
CY2014Q4 us-gaap Disposal Group Including Discontinued Operation Long Lived Assets
DisposalGroupIncludingDiscontinuedOperationLongLivedAssets
0
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1357749
CY2014Q4 us-gaap Deferred Rent Receivables Net
DeferredRentReceivablesNet
97012
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
21697250
CY2014Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
6793705
CY2014Q4 us-gaap Assets
Assets
57263973
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
10816
CY2014Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
22334
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
559470
CY2014Q4 us-gaap Assets Current
AssetsCurrent
56115172
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
55006338
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
819922
CY2014Q4 glyc Restricted Deposits
RestrictedDeposits
57700
CY2014Q4 glyc Deferred Tax Assets Capitalized Start Up Costs
DeferredTaxAssetsCapitalizedStartUpCosts
3264065
CY2014Q4 glyc Deferred Tax Assets Patent Amortization
DeferredTaxAssetsPatentAmortization
260553
CY2014Q4 glyc Deferred Tax Assets Deferred Rent
DeferredTaxAssetsDeferredRent
38266
CY2014Q4 glyc Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
10816
CY2014Q4 glyc Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2726511
CY2014Q4 glyc Accrued License And Milestone Fees
AccruedLicenseAndMilestoneFees
1500000
CY2014Q4 glyc Deferred Tax Asset Recorded To Additional Paid In Capital
DeferredTaxAssetRecordedToAdditionalPaidInCapital
50160
CY2014Q4 glyc Accrued Franchise And Other Taxes
AccruedFranchiseAndOtherTaxes
112511
CY2014Q3 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P8Y
CY2014Q3 glyc Square Feet Under Lease
SquareFeetUnderLease
33843 sqft
CY2009Q4 glyc Shares Issued For Conversion Of Notes Payable And Accrued Interest
SharesIssuedForConversionOfNotesPayableAndAccruedInterest
16099770
CY2006Q4 glyc Issuance Of Warrants To Purchase Common Stock
IssuanceOfWarrantsToPurchaseCommonStock
1544 shares
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.87
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-15539070
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.041 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements
EffectiveIncomeTaxRateReconciliationTaxSettlements
0.000 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.415 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.001 pure
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1196162 shares
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.87
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.077 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.044 pure
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1196162 shares
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1976891
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
558932
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-10606480
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
894
CY2013 us-gaap Revenues
Revenues
3992649
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
82091
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-10605586
CY2013 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
90518
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
425689
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
425689
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3992649
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11701155
CY2013 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2897974
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-15062229
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
369938
CY2013 us-gaap Depreciation
Depreciation
133051
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
558932
CY2013 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
425689
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
187134
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-82091
CY2013 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
14599129
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
380700
CY2013 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2013 glyc Number Of Warrants Exercised
NumberOfWarrantsExercised
0 shares
CY2013 glyc Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
558932
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.70
CY2014 us-gaap Tax Credit Carryforward Expiration Date
TaxCreditCarryforwardExpirationDate
2026-12-31
CY2014 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
CY2014 us-gaap Property Plant And Equipment Basis Of Valuation
PropertyPlantAndEquipmentBasisOfValuation
Cost
CY2014 dei Document Type
DocumentType
10-K
CY2014 dei Entity Registrant Name
EntityRegistrantName
GLYCOMIMETICS INC
CY2014 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2014 dei Trading Symbol
TradingSymbol
GLYC
CY2014 us-gaap Operations Commenced Date1
OperationsCommencedDate1
2003-05-21
CY2014 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2003-04-04
CY2014 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.024 pure
CY2014 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <b>1. Description of the Business</b></p> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> GlycoMimetics, Inc. (the Company), a Delaware corporation headquartered in Gaithersburg, Maryland, was incorporated on April&#xA0;4, 2003 and commenced operations on May&#xA0;21, 2003. The company is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the Company is developing a pipeline of proprietary glycomimetics that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> On January&#xA0;15, 2014, the Company completed an initial public offering of its common stock, which resulted in the sale of 8,050,000 shares, including all additional shares available to cover over-allotments, at a price to the public of $8.00 per share. The Company received net proceeds of approximately $57.2 million.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company&#x2019;s executive personnel have devoted substantially all of their time to date to the planning and organization of the Company, the process of hiring scientists, initiating research and development programs and securing adequate capital for anticipated growth and operations. The Company has not commercialized any of its product candidates and planned commercial operations have not commenced. The Company has incurred significant losses in the development of its product candidates. The losses in prior periods were primarily attributable to the research and development of the Company&#x2019;s lead drug candidate, rivipansel, and the preclinical and manufacturing expenses related to GMI-1271. The Company has not generated revenues from product sales. As a result, the Company has consistently reported negative cash flows from operating activities and net losses, had an accumulated deficit of $74,396,975 at December&#xA0;31, 2014 and expects to continue incurring losses for the foreseeable future. The Company currently anticipates that its cash and cash equivalents will be sufficient to meet its anticipated cash requirements into the second half of 2016.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company&#x2019;s operations are subject to certain risks and uncertainties. The risks include the need to manage growth, the need to retain key personnel, the need to protect intellectual property, the availability of additional capital financing on terms acceptable to the Company and reliance on its collaboration with Pfizer. The Company&#x2019;s current operating assumptions and projections, which reflect management&#x2019;s best estimate of future revenue and operating expenses, indicate that anticipated operating expenditures into the second half of 2016 can be met by available working capital; however, the Company&#x2019;s ability to meet its projections is subject to uncertainties, and there can be no assurance that the Company&#x2019;s current projections will be accurate. If the Company&#x2019;s cash requirements are more than projected, the Company may require additional financing. The type, timing and terms of financing selected by the Company, if required, will be dependent upon the Company&#x2019;s cash needs, the availability of financing sources and the prevailing conditions in the financial markets. There can be no assurance that such financing will be available to the Company at any given time or available on favorable terms.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Management believes that the Company has access to capital resources through private investments of equity from its existing stockholders. However, it has not secured any commitment for new financing as of the date of this report, nor can it provide any assurance that new financing will be available on commercially acceptable terms, if at all. If the Company is unable to secure additional capital, it will be required to curtail its operations, and if these measures fail, it may not be able to continue its business. Curtailment of operations would cause significant delays in the Company&#x2019;s efforts to introduce its products to market, which is critical to the realization of its business plan and the future operations of the Company.</p> </div>
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4281587
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2014 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.3 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.046 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements
EffectiveIncomeTaxRateReconciliationTaxSettlements
0.000 pure
CY2014 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P5Y
CY2014 us-gaap Property Plant And Equipment Depreciation Methods
PropertyPlantAndEquipmentDepreciationMethods
Straight-line basis
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p> </div>
CY2014 dei Document Period End Date
DocumentPeriodEndDate
2014-12-31
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.558 pure
CY2014 dei Amendment Flag
AmendmentFlag
false
CY2014 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18452252 shares
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
CY2014 dei Entity Central Index Key
EntityCentralIndexKey
0001253689
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.074 pure
CY2014 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2014 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Concentration of Credit Risk</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents consist of certificates of deposit and money market funds with major financial institutions in the United States. These deposits and funds may be redeemed upon demand and, therefore, bear minimal risk. The Company does not anticipate any losses on such balances.</p> </div>
CY2014 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.013 pure
CY2014 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18452252 shares
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
57248219
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1656823
CY2014 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1424
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-11139807
CY2014 us-gaap Income Taxes Paid
IncomeTaxesPaid
80000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
18241
CY2014 us-gaap Revenues
Revenues
15027004
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
212603
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-11121566
CY2014 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
103935
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1635065
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1635065
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19571073
CY2014 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6595738
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
52888320
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
385668
CY2014 us-gaap Depreciation
Depreciation
158708
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
57382510
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
57248219
CY2014 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1635065
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4459292
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-212603
CY2014 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
26166811
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-270867
CY2014 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2014 glyc Warrants Exercised Weighted Average Exercise Price
WarrantsExercisedWeightedAverageExercisePrice
0.33
CY2014 glyc Operating Lease Agreements Expiring Date
OperatingLeaseAgreementsExpiringDate
2015-10
CY2014 glyc Lease Agreement Date Of Commencement
LeaseAgreementDateOfCommencement
2015-11-01
CY2014 glyc Stockholder Equity Reverse Stock Split Effective Date
StockholderEquityReverseStockSplitEffectiveDate
2013-10-25
CY2014 glyc Lease Effective Date
LeaseEffectiveDate
2014-07-23
CY2014 glyc Number Of Leases
NumberOfLeases
2 Lease
CY2014 glyc Number Of Warrants Exercised
NumberOfWarrantsExercised
44654 shares
CY2014 glyc Warrant Expiry Period
WarrantExpiryPeriod
2016-10
CY2014 glyc Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
134291
CY2014 glyc Exercise Of Warrants And Stock Options Values
ExerciseOfWarrantsAndStockOptionsValues
134291
CY2014 glyc Increase Decrease In Prepaid Research And Development Expenses
IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses
696531
CY2014 glyc Effect Tax Rate Reconciliation Orphan Tax Credits
EffectTaxRateReconciliationOrphanTaxCredits
0.087 pure
CY2012 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.33
CY2012 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
260913 shares
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10473399
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.055 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements
EffectiveIncomeTaxRateReconciliationTaxSettlements
0.000 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.396 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.001 pure
CY2012 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
520641 shares
CY2012 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11016532 shares
CY2012 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.93
CY2012 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
9305359 shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2012 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
929619 shares
CY2012 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
10000
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
83453
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
237
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
3635029
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
20993
CY2012 us-gaap Revenues
Revenues
15257351
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
316180
CY2012 us-gaap Net Income Loss
NetIncomeLoss
3656022
CY2012 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
48827
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
415208
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
415208
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-14757351
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9438400
CY2012 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2183922
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-10799342
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
321140
CY2012 us-gaap Depreciation
Depreciation
99923
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
237
CY2012 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
415208
CY2012 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
16481
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-326180
CY2012 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
11622322
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
228598
CY2012 glyc Number Of Warrants Exercised
NumberOfWarrantsExercised
0 shares
CY2012 glyc Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
237
CY2013Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
CY2013Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.49
CY2013Q1 us-gaap Revenues
Revenues
3807591
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
459687
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-5101850
CY2013Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.70
CY2013Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.70
CY2013Q2 us-gaap Revenues
Revenues
55074
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-3497060
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.39
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.42
CY2014Q2 us-gaap Revenues
Revenues
15027004
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
7991721
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.00
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.00
CY2013Q3 us-gaap Revenues
Revenues
52571
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-3700885
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-6617577
CY2013Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.80
CY2013Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.80
CY2013Q4 us-gaap Revenues
Revenues
77413
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-3867328
CY2014Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
CY2014Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-7393860

Files In Submission

Name View Source Status
0001193125-15-093802-index-headers.html Edgar Link pending
0001193125-15-093802-index.html Edgar Link pending
0001193125-15-093802.txt Edgar Link pending
0001193125-15-093802-xbrl.zip Edgar Link pending
d838695d10k.htm Edgar Link pending
d838695dex231.htm Edgar Link pending
d838695dex311.htm Edgar Link pending
d838695dex312.htm Edgar Link pending
d838695dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g838695g31j01.jpg Edgar Link pending
g838695g42v01.jpg Edgar Link pending
g838695g58v00.jpg Edgar Link pending
glyc-20141231.xml Edgar Link completed
glyc-20141231.xsd Edgar Link pending
glyc-20141231_cal.xml Edgar Link unprocessable
glyc-20141231_def.xml Edgar Link unprocessable
glyc-20141231_lab.xml Edgar Link unprocessable
glyc-20141231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending